Unique ID issued by UMIN | UMIN000001184 |
---|---|
Receipt number | R000001041 |
Scientific Title | Clinical study of alpha-GalactosylCeramide-pulsed dendritic cells in patients with operable primary lung cancer. |
Date of disclosure of the study information | 2008/06/12 |
Last modified on | 2008/12/11 11:05:12 |
Clinical study of alpha-GalactosylCeramide-pulsed dendritic cells in patients with operable primary lung cancer.
Clinical study of alpha-GalactosylCeramide-pulsed dendritic cells in patients with operable primary lung cancer.
Clinical study of alpha-GalactosylCeramide-pulsed dendritic cells in patients with operable primary lung cancer.
Clinical study of alpha-GalactosylCeramide-pulsed dendritic cells in patients with operable primary lung cancer.
Japan |
primary lung cancer (operable case)
Chest surgery |
Malignancy
NO
The feasibility of alpha-GalactosylCeramide-pulsed dendritic cell and natural killer T (NKT) cell immunotherapy in patients with operable lung cancer are examined. The immunological responses and anti-tumor effects are also investigated.
Safety,Efficacy
Exploratory
Explanatory
Phase I,II
Immunological response
Safety, Clinical response
Interventional
Parallel
Non-randomized
Open -no one is blinded
No treatment
2
Treatment
Medicine | Maneuver |
In patients, intra-venous injection of alpha-GalactosylCeramide pulsed DCs is performed at 1week before operation. Within 3 months after operation he is re-entried, and alpha-GalactosylCeramide pulsed DCs are performed at 1, 2, 7 and 8 weeks after the re-entry.
In control group, intra-venous injection of alpha-GalactosylCeramide pulsed DCs is not performed before and after operation.
20 | years-old | <= |
80 | years-old | >= |
Male and Female
1. Patients between 20 and 80 years of age, with a histologic or cytologic diagnosis of non–small cell lung cancer for which operation is planned.
2. Clinical stage is IIB or IIIA.
3. Performance status of 0, 1, or 2
4. Normal or near normal renal, hepatic, and hematopoietic function
5. NKT cells are detected at least 10 cells in 1 mL of peripheral blood.
1. Patients who have been treated with surgery or chemotherapy or radiotherapy received for at least 4 weeks before enrollment.
2. Histology is large cell neuroendocrine carcinoma.
3. The exclusion criteria were a positive response to HIV, hepatitis C virus, or human T-cell lymphotrophic virus antibodies; positive for hepatitis B antigen; the presence of active inflammatory disease or active autoimmune disease; a history of hepatitis; pregnancy or lactation; concurrent corticosteroid therapy; and evidence for another active malignant neoplasm. The histologic type, tumor-node-metastasis classification, and the antitumor effect of treatment were classified according to the general rules for clinical and pathologic recording of lung cancer as described by the Japan Lung Cancer Society.
20
1st name | |
Middle name | |
Last name | Ichiro Yoshino |
Graduate School of Medicine, Chiba University
Department of Thoracic Surgery
1-8-1 Inohana, Chuo-ku, Chiba, Japan
1st name | |
Middle name | |
Last name |
Graduate School of Medicine, Chiba University
Department of Thoracic Surgery
1-8-1 Inohana, Chuo-ku, Chiba, Japan
043-222-7171
Department of Thoracic Surgery, Graduate School of Medicine, Chiba University
Grant-in-Aid for Scientific Research
Japan
NO
2008 | Year | 06 | Month | 12 | Day |
Unpublished
Completed
2007 | Year | 04 | Month | 01 | Day |
2007 | Year | 11 | Month | 01 | Day |
2009 | Year | 04 | Month | 01 | Day |
2009 | Year | 04 | Month | 01 | Day |
2009 | Year | 04 | Month | 01 | Day |
2009 | Year | 04 | Month | 01 | Day |
2008 | Year | 06 | Month | 11 | Day |
2008 | Year | 12 | Month | 11 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000001041
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |